VIA
ALNY icon

Virtus Investment Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtus Investment Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Buy
9,953
+2,482
+33% +$749K 0.7% 10
2026
Q1 		$2.47M Buy
7,471
+5,754
+335% +$1.96M 0.68% 8
2025
Q4 		$683K Buy
1,717
+258
+18% +$114K 0.19% 182
2025
Q3 		$665K Hold
1,459
– – 0.19% 176
2025
Q2 		$476K Sell
1,459
-8
-0.5% -$2.21K 0.16% 187
2025
Q1 		$396K Buy
+1,467
New +$377K 0.11% 209

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's ALNY Position: Q2 2026 in Review

Virtus Investment Advisers increased its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q2 2026, buying an estimated $749K and bringing the position to 9,953 shares worth $3M. The position accounts for 0.7% of the portfolio, ranked #10.

Virtus Investment Advisers first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. 789 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Virtus Investment Advisers held 9,953 shares of Alnylam Pharmaceuticals worth $3M as of Q2 2026.
  • Virtus Investment Advisers bought 2,482 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $749K.
  • Alnylam Pharmaceuticals made up 0.7% of Virtus Investment Advisers's portfolio in Q2 2026, its #10 holding.
  • Virtus Investment Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.